Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

AUSTIN, Texas, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that implantable paired Vagus Nerve Stimulation (VNS) has been recognized in the 2026 Guideline for Adult Stroke Rehabilitation and Recovery: A Guideline From the American Heart Association (AHA) and American Stroke Association (ASA), published August 27, 2026 in Stroke as a treatment option to improve upper-limb function and impairment for chronic stroke survivors.

Mobia Medical, Inc. (MOBI) Q2 2026 Earnings Call Transcript

Mobia Medical NASDAQ: MOBI reported second-quarter revenue of $13.5 million, up 102% from $6.7 million a year earlier, as adoption of its Vivistim paired vagus nerve stimulation therapy expanded across new and existing stroke-care programs.

AUSTIN, Texas, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today reported financial results for the quarter ended June 30, 2026. Second Quarter 2026 and Recent Highlights Reported revenue of $13.5 million, representing 102% growth over the prior year period Achieved gross margin of 83.2% Announced publication of two-year VNS-REHAB follow up data in Neurology®, demonstrating durable and clinically meaningful improvement in upper-limb motor function, activities of daily living, and quality of life Completed initial public offering, raising approximately $134.0 million in net proceeds Appointed Myriam Curet, M.D.